fenofibrate has been researched along with Diseases, Metabolic in 5 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study included 36 premenopausal women with mixed dyslipidemia and slightly increased prolactin levels, 17 of whom had already been treated with bromocriptine (5." | 7.83 | The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study. ( Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W, 2016) |
| "The study included 36 premenopausal women with mixed dyslipidemia and slightly increased prolactin levels, 17 of whom had already been treated with bromocriptine (5." | 3.83 | The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study. ( Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W, 2016) |
| "Fenofibrate treatment increased fatty acid metabolism further, which reduced postburn hepatic steatosis (burn versus sham P < 0." | 1.39 | Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress. ( Arno, A; Hiyama, Y; Jeschke, MG; Kraft, R; Marshall, AH, 2013) |
| "Treatment with fenofibrate reduced 7 alpha-hydroxycholesterol concentrations in six patients from 107 +/- 47 ng/ml to 61 +/- 12 ng/ml (p < 0." | 1.29 | Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans. ( Hahn, C; von Bergmann, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mueller, R | 1 |
| Yang, J | 1 |
| Duan, C | 1 |
| Pop, E | 1 |
| Geoffroy, OJ | 1 |
| Zhang, LH | 1 |
| Huang, TB | 1 |
| Denisenko, S | 1 |
| McCosar, BH | 1 |
| Oniciu, DC | 1 |
| Bisgaier, CL | 1 |
| Pape, ME | 1 |
| Freiman, CD | 1 |
| Goetz, B | 1 |
| Cramer, CT | 1 |
| Hopson, KL | 1 |
| Dasseux, JL | 1 |
| Mahmoudi, A | 1 |
| Butler, AE | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Hiyama, Y | 1 |
| Marshall, AH | 1 |
| Kraft, R | 1 |
| Arno, A | 1 |
| Jeschke, MG | 1 |
| Krysiak, R | 1 |
| Okrzesik, J | 1 |
| Szkrobka, W | 1 |
| Okopień, B | 1 |
| Hahn, C | 1 |
| von Bergmann, K | 1 |
5 other studies available for fenofibrate and Diseases, Metabolic
| Article | Year |
|---|---|
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
Topics: Alcohols; Animals; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Dicarboxylic Acids; Dose-Re | 2004 |
Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Topics: Computational Biology; Fenofibrate; Humans; Liver; Liver Cirrhosis; Metabolic Diseases; Non-alcoholi | 2021 |
Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Burns; Endoplasmic Reticulum Stress; Fatty Acids; Fatty Liver; Fenofibrate; Hepa | 2013 |
The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemi | 2016 |
Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans.
Topics: Acyl Coenzyme A; Adolescent; Adult; Aged; Bile Acids and Salts; Child; Child, Preschool; Feces; Fema | 1996 |